PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. (PMVP): 3 pipeline candidates · 2 upcoming catalysts · ~14 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.9 months
D/E 0.10 · 0% dilution
Lead: Phase 2
3 candidates
2 upcoming, next in ~2509d
N/A
A transparent, data-derived signal for PMV Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$56.5M
Cash
$39.1M
Quarterly Burn
$19.7M
Runway
13.9 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| pc14586 | Phase 2 |
| rezatapopt | Phase 1/Phase 2 |
| rosuvastatin | Phase 1 |
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
65
Total value held
$29.3M
| Holder | Shares | Value |
|---|---|---|
| tang capital management llc | 4,245,085 | $5.3M |
| vanguard capital management llc | 3,949,812 | $4.9M |
| euclidean capital llc | 2,627,643 | $3.3M |
| two sigma investments, lp | 1,884,530 | $2.3M |
| adage capital partners gp, l.l.c. | 1,860,000 | $2.3M |
| blackrock, inc. | 874,374 | $1.1M |
| morgan stanley | 864,311 | $1.1M |
| stonepine capital management, llc | 708,102 | $878K |
| walleye capital llc | 671,388 | $833K |
| longaeva partners l.p. | 552,027 | $685K |
Showing top 10 of 65 institutional holders of PMV Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PMV Pharmaceuticals, Inc.'s pipeline?
PMV Pharmaceuticals, Inc. (PMVP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PMV Pharmaceuticals, Inc.'s lead drug candidate?
PMV Pharmaceuticals, Inc.'s most advanced tracked candidate is pc14586 (Phase 2) for Locally advanced or metastatic solid tumors with a p53 Y220C mutation.
What is PMV Pharmaceuticals, Inc.'s next catalyst?
PMV Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ROSZET" — expected May 1, 2033.
What is PMV Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PMV Pharmaceuticals, Inc. has approximately 13.9 months of cash runway.
What is PMV Pharmaceuticals, Inc.'s market capitalization?
PMV Pharmaceuticals, Inc.'s market capitalization is approximately $56.5M.
Get the full picture on PMV Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.